• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    MIMEDX Announces Appointment of Two New Independent Directors

    3/4/24 8:00:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MDXG alert in real time by email

    MARIETTA, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. Ms. Olson and Ms. Puhy each bring extensive and relevant experience across the healthcare industry, with demonstrated records of executive leadership, strategic counsel and shareholder value creation. In connection with these appointments, the Board of Directors unanimously agreed to expand its size to eleven directors.

    M. Kathleen Behrens, Chair of the Board at MIMEDX, stated, "On behalf of the entire Board of Directors, we are honored to welcome these accomplished business leaders who will undoubtedly contribute to our strategic vision and provide unique and valuable insights. We look forward to working together to unlock the full potential MIMEDX has to offer the industry as a leader in innovative Wound Care and Surgical therapeutics."

    Joseph H. Capper, MIMEDX Chief Executive Officer, added, "Tiffany and Dorothy will be exceptional additions to the Board. These individuals have highly complementary skill sets, which, coupled with their proven track records of leadership and influence at prominent organizations across healthcare and other industries, will elevate our Board as a whole."

    About Tiffany Olson

    Ms. Olson currently serves as a board member for two other public companies, Telix Pharmaceuticals and Castle Biosciences, and a privately held growth-stage company, Langham Logistics. She previously held CEO, president, and senior leadership positions in the U.S. and Europe at multiple international Fortune 100 healthcare companies, including Cardinal Health, Roche, and Eli Lilly.

    About Dorothy Puhy

    Ms. Puhy has previously held board positions at Abiomed, Azenta, Eaton Vance, Reebok, and other privately held companies. She has also held several executive leadership positions, including CFO and EVP, COO of Dana-Farber Cancer Institute and EVP, CFO of New England Medical Center (now Tufts Medical Center).

    About MIMEDX

    MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company's vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

    Contact:

    Matt Notarianni

    Investor Relations

    470-304-7291

    [email protected]



    Primary Logo

    Get the next $MDXG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDXG

    DatePrice TargetRatingAnalyst
    7/2/2024$11.00Overweight
    Cantor Fitzgerald
    3/7/2024$12.00Buy
    Lake Street
    10/27/2023$12.00Buy
    Craig Hallum
    10/13/2022$7.00Buy
    Mizuho
    9/14/2021$20.00 → $8.50Buy
    HC Wainwright & Co.
    7/26/2021$23.00Outperform
    Northland Capital
    More analyst ratings

    $MDXG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on MiMedx Group with a new price target

      Cantor Fitzgerald initiated coverage of MiMedx Group with a rating of Overweight and set a new price target of $11.00

      7/2/24 7:38:13 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lake Street initiated coverage on MiMedx Group with a new price target

      Lake Street initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $12.00

      3/7/24 8:26:30 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Craig Hallum initiated coverage on MiMedx Group with a new price target

      Craig Hallum initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $12.00

      10/27/23 9:04:53 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDXG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Capper Joseph H bought $1,268,000 worth of shares (200,000 units at $6.34), increasing direct ownership by 61% to 529,530 units (SEC Form 4)

      4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

      5/5/25 10:06:51 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Doug Rice bought $35,786 worth of shares (5,000 units at $7.16), increasing direct ownership by 5% to 102,200 units (SEC Form 4)

      4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

      11/22/23 5:01:18 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDXG
    SEC Filings

    See more
    • MiMedx Group Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - MIMEDX GROUP, INC. (0001376339) (Filer)

      6/20/25 4:05:14 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by MiMedx Group Inc

      DEFA14A - MIMEDX GROUP, INC. (0001376339) (Filer)

      5/23/25 4:15:14 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MiMedx Group Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - MIMEDX GROUP, INC. (0001376339) (Filer)

      5/13/25 4:08:09 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care